United States — Food and Drug Administration & Replimune Group

United States — Food and Drug Administration: The United States — Food and Drug Administration accepted the resubmission of the Biologics License Application for RP1, setting a target action date and scheduling an advisory committee meeting, which are crucial steps in the regulatory process for Replimune Group's drug.

Replimune Group: The FDA's acceptance of the BLA resubmission for RP1 is a significant step towards potential accelerated approval, which could lead to increased revenue and market presence for Replimune Group. However, the stock price was down in pre-market trading, indicating some investor caution.

Replimune Group: Replimune Group is the target of multiple class action lawsuits due to alleged false statements regarding its IGNYTE trial, which led to the United States — Food and Drug Administration deeming the trial inadequate.

Replimune Group: Replimune Group>>> experienced rejection of its melanoma therapy by the United States — Food and Drug Administration>>> under Marty Makary>>>'s leadership, leading to public criticism and contributing to the pressure for his ouster.